Collier announced that the company plans to acquire 85% of Shenzhen Baochun Meilai Biotechnology Co., Ltd.'s shares in cash at a transaction price of 2.19 million yuan. This transaction constitutes a related transaction and does not constitute a major asset restructuring. The counterparty, Shenzhen Baochuntang, is an enterprise controlled by Nie Baosheng and Nie Pengju, the actual controllers of the company. The relevant directors have already avoided voting. The transaction is based on the target company's audited net assets. The pricing is fair, which helps the company quickly enter terminal consumer product sales and accelerate the development of the terminal consumer business.

Collier announced that the company plans to acquire 85% of Shenzhen Baochun Meilai Biotechnology Co., Ltd.'s shares in cash at a transaction price of 2.19 million yuan. This transaction constitutes a related transaction and does not constitute a major asset restructuring. The counterparty, Shenzhen Baochuntang, is an enterprise controlled by Nie Baosheng and Nie Pengju, the actual controllers of the company. The relevant directors have already avoided voting. The transaction is based on the target company's audited net assets. The pricing is fair, which helps the company quickly enter terminal consumer product sales and accelerate the development of the terminal consumer business.